Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy. STEVE INSKEEP, HOST: The next generation of obesity medication is getting closer to reality. Eli Lilly is studying a new drug. Test results show it's more powerful, even more powerful than the obesity shots and pills already on the market. …